Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Manfredi

Showing results (91-100 of 114) with videos related to

Pageof 12
Sort By:
Drugs in R&D|November 27, 2023
Drug-Drug Interaction Studies of Esmethadone (REL-1017) Involving CYP3A4- and CYP2D6-Mediated MetabolismNicola Ferri, Sara De Martin, James Stuart, et al.
Neuro-Degenerative Diseases|March 7, 2008
Duodenal levodopa infusion improves quality of life in advanced Parkinson's diseaseA Antonini, F Mancini, M Canesi, et al.
Drugs in R&D|August 2, 2024
Pharmacokinetics, Tolerability, and Safety of Esmethadone in Subjects with Chronic Kidney Disease or Hepatic ImpairmentNicola Ferri, Sara De Martin, James Stuart, et al.
Frontiers in Pharmacology|May 17, 2021
REL-1017 (Esmethadone) Increases Circulating BDNF Levels in Healthy Subjects of a Phase 1 Clinical StudySara De Martin, Daniela Gabbia, Franco Folli, et al.
Journal of Clinical Psychopharmacology|August 9, 2022
REL-1017 (Esmethadone) May Rapidly Reduce Dissociative Symptoms in Adults With Major Depressive Disorder Unresponsive to Standard Antidepressants: A Report of 2 CasesClotilde Guidetti, Giulia Serra, Luca Pani, et al.
Molecular Psychiatry|May 28, 2024
Letter to the Editor regarding 'Unique pharmacodynamic properties and low abuse liability of the µ-opioid receptor ligand (S)-methadone'Marco Pappagallo, Thomas R Kosten, Charles W Gorodetzky, et al.
Scientific Reports|July 6, 2022
REL-1017 (esmethadone; D-methadone) does not cause reinforcing effect, physical dependence and withdrawal signs in Sprague Dawley ratsJack Henningfield, David Gauvin, Francesco Bifari, et al.
The American Journal of Psychiatry|September 1, 1994
Diagnostic concordance for DSM-IV sleep disorders: a report from the APA/NIMH DSM-IV field trialD J Buysse, C F Reynolds, P J Hauri, et al.
Journal of Medicinal Chemistry|February 25, 2025
New Synthesis and Pharmacological Evaluation of Enantiomerically Pure (<i>R</i>)- and (<i>S</i>)-Methadone Metabolites as <i>N</i>-Methyl-d-aspartate Receptor AntagonistsMarco Banzato, Alberto Furlan, Patrizia Locatelli, et al.
Journal of Medicinal Chemistry|January 26, 2026
Design, Synthesis, and Pharmacokinetic Profiling of Fluorinated Reversible <i>N</i>-Alkyl Carbamate Derivatives of Psilocin for Sub-Hallucinogenic Brain ExposureMarco Banzato, Martina Colognesi, Lorena Lucatello, et al.
Pageof 12

Showing results (91-100 of 114) with videos related to

Sort By:
Pageof 12
Drugs in R&D|November 27, 2023
Drug-Drug Interaction Studies of Esmethadone (REL-1017) Involving CYP3A4- and CYP2D6-Mediated MetabolismNicola Ferri, Sara De Martin, James Stuart, et al.
Neuro-Degenerative Diseases|March 7, 2008
Duodenal levodopa infusion improves quality of life in advanced Parkinson's diseaseA Antonini, F Mancini, M Canesi, et al.
Drugs in R&D|August 2, 2024
Pharmacokinetics, Tolerability, and Safety of Esmethadone in Subjects with Chronic Kidney Disease or Hepatic ImpairmentNicola Ferri, Sara De Martin, James Stuart, et al.
Frontiers in Pharmacology|May 17, 2021
REL-1017 (Esmethadone) Increases Circulating BDNF Levels in Healthy Subjects of a Phase 1 Clinical StudySara De Martin, Daniela Gabbia, Franco Folli, et al.
Journal of Clinical Psychopharmacology|August 9, 2022
REL-1017 (Esmethadone) May Rapidly Reduce Dissociative Symptoms in Adults With Major Depressive Disorder Unresponsive to Standard Antidepressants: A Report of 2 CasesClotilde Guidetti, Giulia Serra, Luca Pani, et al.
Molecular Psychiatry|May 28, 2024
Letter to the Editor regarding 'Unique pharmacodynamic properties and low abuse liability of the µ-opioid receptor ligand (S)-methadone'Marco Pappagallo, Thomas R Kosten, Charles W Gorodetzky, et al.
Scientific Reports|July 6, 2022
REL-1017 (esmethadone; D-methadone) does not cause reinforcing effect, physical dependence and withdrawal signs in Sprague Dawley ratsJack Henningfield, David Gauvin, Francesco Bifari, et al.
The American Journal of Psychiatry|September 1, 1994
Diagnostic concordance for DSM-IV sleep disorders: a report from the APA/NIMH DSM-IV field trialD J Buysse, C F Reynolds, P J Hauri, et al.
Journal of Medicinal Chemistry|February 25, 2025
New Synthesis and Pharmacological Evaluation of Enantiomerically Pure (<i>R</i>)- and (<i>S</i>)-Methadone Metabolites as <i>N</i>-Methyl-d-aspartate Receptor AntagonistsMarco Banzato, Alberto Furlan, Patrizia Locatelli, et al.
Journal of Medicinal Chemistry|January 26, 2026
Design, Synthesis, and Pharmacokinetic Profiling of Fluorinated Reversible <i>N</i>-Alkyl Carbamate Derivatives of Psilocin for Sub-Hallucinogenic Brain ExposureMarco Banzato, Martina Colognesi, Lorena Lucatello, et al.
Pageof 12